Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

Valentina Boldrini, Paola Guglielmelli, Giada Rotunno, Chiara Maccari, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Naseema Gangat, Ayalew Tefferi, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2023-189571

Published: 2023

Journal Articles

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2023-184845

Published: 2023

Journal Articles

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Blood (2023) 142 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2023-173574

Published: 2023

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Journal Articles

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Blood (2023) 142 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2023-178599

Published: 2023

Journal Articles

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Matteo Piccini, Sofia Pilerci, Barbara Scappini, Francesco Mannelli, Gaia Ciolli, Andrea Pasquini, Laura Fasano, Elisa Quinti, Paola Guglielmelli, Carmela Mannarelli, Fabiana Pancani, Michela Zizza, Leonardo Signori, Alessandro M. Vannucchi, Giacomo Gianfaldoni

Blood (2022) 140 (Supplement 1): 9008–9009.

https://doi.org/10.1182/blood-2022-163212

Published: 2022

Journal Articles

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Chiara Paoli, Paola Guglielmelli, Francesco Mannelli, Miriam Borella, Vittorio Rosti, Elisa Rumi, Maria Chiara Finazzi, Oscar Borsani, Carmela Mannarelli, Maria Esposito, Mario Xhani, Lisa Pieri, Tiziano Barbui, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 6840–6841.

https://doi.org/10.1182/blood-2022-156566

Published: 2022

Journal Articles

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Paola Guglielmelli, Fiorenza Irushani Vanderwert, Simone Romagnoli, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Laura Calabresi, Giulia Gentili, Giada Rotunno, Niccolò Bartalucci, Valentina Boldrini, Emanuela Sant'Antonio, Danilo Tarantino, Marco Pieraccioli, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 832–833.

https://doi.org/10.1182/blood-2022-156776

Published: 2022

Journal Articles

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Giuseppe Gaetano Loscocco, Raffaella Santi, Carmela Mannarelli, Francesco Mannelli, Francesca Gesullo, Giacomo Coltro, Paola Guglielmelli, Umberto Gianelli, Alessandro M Vannucchi

Blood (2022) 140 (Supplement 1): 9714–9716.

https://doi.org/10.1182/blood-2022-167880

Published: 2022

Journal Articles

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Blood (2022) 140 (Supplement 1): 9685–9687.

https://doi.org/10.1182/blood-2022-156371

Published: 2022

Journal Articles

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Fabiana Pancani, Ilaria Colugnat, Raffaela Aquila, Elena Nacca, Paolo Cicogna, Francesco Passamonti, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 1788–1789.

https://doi.org/10.1182/blood-2022-156781

Published: 2022

Journal Articles

A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count

Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, Natasha Szuber, Francesco Mannelli, Animesh D. Pardanani, Curtis A. Hanson, Valerio De Stefano, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 238.

https://doi.org/10.1182/blood-2021-149140

Published: 2021

Journal Articles

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

Giuseppe Gaetano Loscocco, Paola Guglielmelli, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 237.

https://doi.org/10.1182/blood-2021-147869

Published: 2021

Journal Articles

Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis

Giacomo Coltro, Paola Guglielmelli, Giada Rotunno, Carmela Mannarelli, Chiara Maccari, Costanza Salvadori, Fiorenza Irushani Vanderwert, Francesco Mannelli, Cristina Salvati, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 2578.

https://doi.org/10.1182/blood-2021-148685

Published: 2021

Journal Articles

A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis

Giacomo Coltro, Francesco Mannelli, Giuseppe Gaetano Loscocco, Carmela Mannarelli, Giada Rotunno, Chiara Maccari, Fabiana Pancani, Alessandro Atanasio, Ayalew Tefferi, Alessandro Vannucchi, Paola Guglielmelli

Blood (2021) 138 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2021-146600

Published: 2021

Journal Articles

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

Fiorenza Irushani Vanderwert, Benedetta Sordi, Francesco Mannelli, Boaz Palterer, Francesca Gesullo, Valentina Mecheri, Raffaella Santi, Carmela Mannarelli, Francesca Crupi, Roberta Zanotti, Federica Irene Grifoni, Chiara Elena, Roberta Parente, Massimo Triggiani, Pieri Lisa, Fabio Almerigogna, Paola Guglielmelli, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2021-148154

Published: 2021

Journal Articles

Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms

Paola Guglielmelli, Laura Calabresi, Chiara Carretta, Giada Rotunno, Sandra Parenti, Simone Romagnoli, Selene Mallia, Niccolò Bartalucci, Sebastiano Rontauroli, Chiara Chiereghin, Sara Castellano, Francesco Mannelli, Matteo G. Della Porta, Rossella Manfredini, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 56.

https://doi.org/10.1182/blood-2021-148315

Published: 2021

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

NARROW

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis

A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only